Literature DB >> 23303061

Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.

Francis E Lotrich1, Salwa Albusaysi, Robert E Ferrell.   

Abstract

Depression has been associated with inflammation, and inflammation may both influence and interact with growth factors such as brain-derived neurotrophic factor (BDNF). Both the functional Val66Met BDNF polymorphism (rs6265) and BDNF levels have been associated with depression. It is thus plausible that decreased BDNF could mediate and/or moderate cytokine-induced depression. We therefore prospectively employed the Beck Depression Inventory-II (BDI-II), the Hospital Anxiety and Depression Scale (HADS), and the Montgomery-Asberg Depression Rating Scale (MADRS) in 124 initially euthymic patients during treatment with interferon-alpha (IFN-α), assessing serum BDNF and rs6265. Using mixed-effect repeated measures, lower pretreatment BDNF was associated with higher depression symptoms during IFN-α treatment (F144,17.2=6.8; P<0.0001). However, although the Met allele was associated with lower BDNF levels (F1,83.0=5.0; P=0.03), it was only associated with increased MADRS scores (F4,8.9=20.3; P<0.001), and not the BDI-II or HADS. An exploratory comparison of individual BDI-II items indicated that the Met allele was associated with suicidal ideation, sadness, and worthlessness, but not neurovegetative symptoms. Conversely, the serotonin transporter promoter polymorphism (5-HTTLPR) short allele was associated with neurovegetative symptoms such as insomnia, poor appetite and fatigue, but not sadness, worthlessness, or suicidal ideation. IFN-α therapy further lowered BDNF serum levels (F4,37.7=5.0; P=0.003), but this decrease occurred regardless of depression development. The findings thus do not support the hypothesis that decreasing BDNF is the primary pathway by which IFN-α worsens depression. Nonetheless, the results support the hypothesis that BDNF levels influence resiliency against developing inflammatory cytokine-associated depression, and specifically to a subset of symptoms distinct from those influenced by 5-HTTLPR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23303061      PMCID: PMC3629388          DOI: 10.1038/npp.2012.263

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  127 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment.

Authors:  Catharine H Duman; Lee Schlesinger; Masafumi Kodama; David S Russell; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2006-08-30       Impact factor: 13.382

3.  Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients.

Authors:  Luisella Bocchio-Chiavetto; Roberta Zanardini; Marco Bortolomasi; Maria Abate; Matilde Segala; Mario Giacopuzzi; Marco Andrea Riva; Eleonora Marchina; Patrizio Pasqualetti; Jorge Perez; Massimo Gennarelli
Journal:  Eur Neuropsychopharmacol       Date:  2006-06-06       Impact factor: 4.600

4.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

5.  Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors.

Authors:  M Besser; R Wank
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

6.  Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders.

Authors:  Benjamin I Goldstein; Katelyn A Collinger; Francis Lotrich; Anna L Marsland; Mary-Kay Gill; David A Axelson; Boris Birmaher
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-10       Impact factor: 2.576

7.  Brain-derived neurotrophic factor selectively enhances allergen-specific IgE production.

Authors:  H Kimata
Journal:  Neuropeptides       Date:  2005-08       Impact factor: 3.286

8.  Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality.

Authors:  Aric A Prather; Mordechai Rabinovitz; Bruce G Pollock; Francis E Lotrich
Journal:  Brain Behav Immun       Date:  2009-07-15       Impact factor: 7.217

9.  Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.

Authors:  Francis E Lotrich; Bruce G Pollock; Margaret Kirshner; Robert F Ferrell; Charles F Reynolds Iii
Journal:  J Psychiatry Neurosci       Date:  2008-03       Impact factor: 6.186

10.  The effect of depression, BDNF gene val66met polymorphism and gender on serum BDNF levels.

Authors:  Erol Ozan; Hamza Okur; Cağdaş Eker; Ozlem D Eker; Ali Saffet Gönül; Nurten Akarsu
Journal:  Brain Res Bull       Date:  2010-01-15       Impact factor: 4.077

View more
  31 in total

1.  Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  J Psychosom Res       Date:  2013-07-26       Impact factor: 3.006

Review 2.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 3.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

4.  Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer.

Authors:  Larissa N Dooley; Patricia A Ganz; Steve W Cole; Catherine M Crespi; Julienne E Bower
Journal:  J Affect Disord       Date:  2016-03-02       Impact factor: 4.839

Review 5.  Sick and tired: mood, fatigue, and inflammation in cancer.

Authors:  Jennifer L Kruse; Thomas B Strouse
Journal:  Curr Psychiatry Rep       Date:  2015-03       Impact factor: 5.285

6.  Effects of Fatigue on Balance in Individuals With Parkinson Disease: Influence of Medication and Brain-Derived Neurotrophic Factor Genotype.

Authors:  Michael Baer; Bradley Klemetson; Diana Scott; Andrew S Murtishaw; James W Navalta; Jefferson W Kinney; Merrill R Landers
Journal:  J Neurol Phys Ther       Date:  2018-04       Impact factor: 3.649

7.  Effects of Agmatine on Depressive-Like Behavior Induced by Intracerebroventricular Administration of 1-Methyl-4-phenylpyridinium (MPP(+)).

Authors:  Morgana Moretti; Vivian Binder Neis; Filipe Carvalho Matheus; Mauricio Peña Cunha; Priscila Batista Rosa; Camille Mertins Ribeiro; Ana Lúcia S Rodrigues; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2015-07-09       Impact factor: 3.911

8.  Polyunsaturated fatty acids moderate the effect of poor sleep on depression risk.

Authors:  Francis E Lotrich; Barry Sears; Robert K McNamara
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2015-11-10       Impact factor: 4.006

9.  Depression in Late-Life: a Focus on Prevention.

Authors:  Olivia I Okereke; Jeffrey M Lyness; Francis E Lotrich; Charles F Reynolds
Journal:  Focus (Am Psychiatr Publ)       Date:  2013

Review 10.  Fighting insomnia and battling lethargy: the yin and yang of palliative care.

Authors:  Mellar P Davis; Harold Goforth
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.